Verastem (VSTM) Gains from Investment Securities (2023 - 2026)
Verastem (VSTM) posted quarterly Gains from Investment Securities of -$9.3 million for Q1 2026, down 485.89% year-over-year from $2.4 million in Q1 2025, and up 11.08% quarter-over-quarter from -$10.5 million in Q4 2025.
Analysis
Verastem (VSTM) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Verastem's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 485.89% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at $15.8 million (down 72.37% YoY), while the FY2025 annual figure was $27.5 million, up 43.57% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$9.3 million, up from -$10.5 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $55.9 million in Q3 2025, with the low at -$20.3 million in Q2 2025.
- The 4-year median for Gains from Investment Securities is $5.5 million (2023), against an average of $9.1 million.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities soared 313.93% in 2025, then slumped 485.89% in 2026.
- Verastem's Gains from Investment Securities stood at $8.5 million in 2023, then soared by 284.08% to $32.6 million in 2024, then sank by 132.16% to -$10.5 million in 2025, then grew by 11.08% to -$9.3 million in 2026.
- Business Quant data shows VSTM's Gains from Investment Securities at -$9.3 million in Q1 2026, -$10.5 million in Q4 2025, and $55.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -9.32 Mn |
| Dec 31, 2025 | -10.49 Mn |
| Sep 30, 2025 | 55.88 Mn |
| Jun 30, 2025 | -20.32 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 32.61 Mn |
| Sep 30, 2024 | 13.50 Mn |
| Jun 30, 2023 | 8.49 Mn |